Usefulness of neutrophil-to-lymphocyte ratios to predict pathologic response and prognosis in patients with operable breast cancer receiving neoadjuvant chemotherapy with nab-paclitaxel

被引：0
|
作者：
Yugo, N. [1 ]
Mizuno, Y. [1 ]
机构：
[1] Yokkaichi Municipal Hosp, Breast Surg Dept, Yokaichi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22P
引用
收藏
页码：S1412 / S1412
页数：1
相关论文
共 50 条
  • [41] A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer
    Werner, Theresa L.
    Ray, Abhijit
    Lamb, John G.
    VanBrocklin, Matthew
    Hueftle, Kristin
    Cohen, Adam L.
    Beck, Anna C.
    Buys, Saundra S.
    Dyess, Donna L.
    Butler, Thomas W.
    Dumlao, Theresa L.
    Neumayer, Leigh
    Khong, Hung T.
    CLINICAL BREAST CANCER, 2017, 17 (07) : 503 - 509
  • [42] Neoadjuvant Chemotherapy for Breast Cancer with Weekly Nab-paclitaxel Followed by Epirubicin and Cyclophosphamide - Results of a Case Series
    Hahn, Antje
    Schlotter, Claus M.
    Rossmanith, Winfried G.
    Ulmer, Hans-Ulrich
    Staiger, Hans-Juergen
    Villena, Carlos
    IN VIVO, 2014, 28 (02): : 235 - 241
  • [43] Neutrophil-to-lymphocyte ratio as a prognostic factor for neoadjuvant chemotherapy for locally advanced breast cancer
    Alshamsan, B.
    Aseafan, M. J.
    Fahmy, N.
    Badran, A.
    Elhassan, T.
    Elshenawy, M. A.
    Alsayed, A.
    Suleman, K.
    Ajarim, D. S.
    Al-Tweigeri, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S344 - S344
  • [44] Neutrophil-lymphocyte ratio and nodal pathologic complete response in node positive breast cancer patients undergoing neoadjuvant chemotherapy
    Gasparri, M. L.
    Di Micco, R.
    Bassi, V.
    Sevas, V.
    Meani, F.
    Papadia, A.
    Gentilini, O. D.
    BREAST, 2021, 56 : S66 - S66
  • [45] Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study
    Chen, Yi
    Chen, Kai
    Xiao, Xiaoyun
    Nie, Yan
    Qu, Shaohua
    Gong, Chang
    Su, Fengxi
    Song, Erwei
    BMC CANCER, 2016, 16
  • [46] Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study
    Yi Chen
    Kai Chen
    Xiaoyun Xiao
    Yan Nie
    Shaohua Qu
    Chang Gong
    Fengxi Su
    Erwei Song
    BMC Cancer, 16
  • [47] Weekly nab-paclitaxel followed by FEC in patients with operable breast cancer: Phase II study.
    Seki, Hirohito
    Asamuna, Fumiki
    Morinaga, Shyoujiro
    Suzuki, Keiichi
    Kaneda, Munehisa
    Kamiya, Noriki
    Ishii, Yoshiyuki
    Osaku, Masayoshi
    Ikeda, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [48] Pathologic response to neoadjuvant therapy with nab-paclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.
    Cardenas, Juan David
    Martinez, Elia
    Alba, Blanca Lourdes Trujillo
    Esteban, Carmen Esteban
    Salvador, Ana Rosa Rubio
    Barahona, Ana Dominguez
    Romero, Cristina
    Sanchez-Simon, Raquel
    Garcia Avila, Maria
    Ignacio Chacon, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Pretreatment neutrophil-to-lymphocyte ratio (NLR) correlates with response to neoadjuvant chemotherapy and survival in breast cancer: A pilot study
    Bruixola, G.
    Nino Gomez, O.
    Salvador, C.
    Reche, E.
    Escoin, C.
    Akhoundova, D.
    Palomar, L.
    De la Cueva, H.
    Ripoll, F.
    Garcia Martinez, A.
    Santaballa, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S325 - S325
  • [50] Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predict Poor Survival in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy
    Ke, T. M.
    Yang, C. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E166 - E166
12345